Browse
Submit Data
Databases
API
Help

Dataset Information

30 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Monoclonal antibodies as treatment for COVID-19 Anticuerpos monoclonales Como medida de tratamiento Para los pacientes con la COVID-19

ABSTRACT:

SUBMITTER: Medina Gamero A

PROVIDER: S-EPMC8527594 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Diagnosis and locoregional treatment of patients with breast cancer during the COVID-19 pandemic Diagnostico y tratamiento locorregional de las pacientes con cancer de mama durante la pandemia de la COVID-19

Project description:We are facing a pandemic that is going to affect a significant part of the population. At the end of April in the world there are about 3,000,000 cases, with 205,000 deaths and 860,000 patients recovered. The response to this pandemic has in many cases led to a significant change in the daily work of caring for cancer patients, the good results of which depend largely on time-adjusted protocols and multidisciplinary treatments. We present a review of local, surgical and radiotherapy treatment together with authors’ recommendations made from personal experience on ways to act in the diagnosis and surgical treatment of breast cancer during the COVID-19 pandemic. The multidisciplinary Breast Committees must continue to meet weekly in videoconference format. All surgical actions and irradiations must be carried out with maximum safety for both the patients and the participating teams. Hypofractionation in radiation therapy should be the standard treatment. Sometimes it is recommended to apply a primary systemic treatment or even a primary irradiation. Great coordination between the surgical and oncology teams, both medical and radiotherapeutic, is essential.

| S-EPMC7198217 | biostudies-literature

Impact of drug interactions with direct oral anticoagulants on mortality in elderly with atrial fibrillation during the COVID-19 pandemic Impacto de la interaccion de farmacos con los anticoagulantes orales directos en la mortalidad de pacientes mayores con fibrilacion auricular durante la pandemia por COVID-19

Project description:Objective To evaluate the effect of drug interactions with chronic direct oral anticoagulants (DOAC) on mortality in older atrial fibrillation (AF) patients during the Coronavirus disease 2019(COVID-19) pandemic. Methods We followed a total of 601 elderly patients (65 years of age) from the NOEL-Drug Registry cohort who were referred to a tertiary outpatient clinic between 9 March 2020 and 1 March 2021. We recorded clinical characteristics and medications for the last 3 months. In addition, all drug interactions were identified using Lexicomp®. Finally, we recorded retrospectively all death events, COVID-19 diagnosis, and relevant deaths from the database at the end of the study. According to logistic regression, we performed propensity score (PS) matching to reduce potential bias. Factors associated with total mortality in the 12 months were analyzed using multivariable Cox proportion hazard analysis. Results The mean age [standard deviation (SD)] was 74.5 (±6.9), and the male/female ratio was 337/264. The prevalence of total mortality was 16.9% (n = 102). A total of 4472 drugs were analyzed for DOAC interaction. 81.8% of older AF patients were not at risk in terms of potential interaction. In the Cox proportional hazard model after PS-matching, previous DOAC use with class X interaction was associated with significantly higher mortality risk (adjusted hazard ratio: 2.745, 95% confidence interval: 1.465–5.172, p = 0.004). Conclusions Our study showed that while most co-medications do not have significant interactions with DOACs, few serious drug interactions contribute to mortality in elderly patients with AF during the pandemic.

| S-EPMC9283695 | biostudies-literature

HLA genetic polymorphisms and prognosis of patients with COVID-19 Polimorfismos geneticos de los HLA y pronostico de pacientes con COVID-19

Project description:Objective Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients. Design Observational and prospective study. Setting Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain). Patients COVID-19 patients admitted in ICU and healthy subjects. Interventions Determination of HLA genetic polymorphisms. Main variable of interest Mortality at 30 days. Results A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 (p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 (p = 0.02) and HLA-C*16 (p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02), the allele HLA-C*01 after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02), and the allele HLA-DQB1*04 after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03). Conclusions The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn.

| S-EPMC7905376 | biostudies-literature

Estudio abierto, no aleatorizado, multicéntrico, en fase II, para evaluar la eficacia y seguridad de Bevacizumab en combinación con Capecitabina y Oxaliplatino, como primera línea de tratamiento en pacientes ancianos con adenocarcinoma colorrectal metastásico indicados para recibir tratamiento poliquimioterápico

Project description:Primary objectives: El objetivo principal del estudio es determinar el tiempo libre de progresión de la enfermedad en los pacientes ancianos sometidos al tratamiento de estudio Primary endpoints: El parámetro principal de eficacia es tiempo libre de progresión, definido como el tiempo desde el inicio del tratamiento, hasta que se objetiva enfermedad progresiva según los criterios RECIST

| 2526016 | ecrin-mdr-crc

Uso terapeutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda» Therapeutic use of angiotensin converting enzyme inhibitors in patients with COVID-19: the “two sides of the coin”

Project description:La evidencia actual es limitada para determinar el impacto del uso de los inhibidores de la enzima convertidora de angiotensina (IECA) en la predisposición al empeoramiento de la enfermedad del coronavirus 2019 (COVID-19). Inicialmente se reportó que en los pacientes con progresión grave de la COVID-19 existía una mortalidad elevada, los cuales tenían antecedentes de hipertensión arterial, diabetes mellitus, enfermedad cardiovascular y enfermedad renal crónica. Parte de estos pacientes también tenía en común que utilizaban IECA, lo cual alertó a la comunidad médica sobre su riesgo potencial en coexistencia con COVID-19. Sin embargo, estudios más recientes de casos-controles encontraron que los inhibidores del sistema renina-angiotensina, incluyendo los IECA, no incrementan el riesgo de COVID-19 o de requerir admisión hospitalaria por esta causa. Diferentes revistas científicas han facilitado el acceso a reportes preliminares, dejando a discreción de la comunidad médica y científica hacer uso de dicha información para promover el desarrollo de estudios que confirmen experimentalmente dichos hallazgos, preclínicos y epidemiológicos, que finalmente impacten en las decisiones de la práctica clínica para beneficiar a los pacientes con COVID-19. En esta revisión de la literatura se exploran los diferentes efectos mediados por los IECA que podrían estar relacionados con la respuesta inmune durante la infección y la transmisión de COVID-19, compilando evidencia disponible que evalúa si en realidad representan un riesgo o si, por el contrario, confieren un efecto protector.

| S-EPMC7365126 | biostudies-literature

Surgical Management of Patients With COVID-19 Infection. Recommendations of the Spanish Association of Surgeons☆ Manejo quirurgico de pacientes con infeccion por COVID-19. Recomendaciones de la Asociacion Espanola de Cirujanos

Project description:Due to the current pandemic of respiratory disease known as coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, many patients with confirmed or suspected COVID-19 infection will require elective surgery, surgery that cannot be postponed, or emergency surgical treatment. In these situations, special measures need to be adopted in order to minimize the possibility of transmission between patients, exposure of healthcare personnel and the development of postoperative complications. This document explains the main principles to consider when managing confirmed or suspected COVID-19 patients during evaluation as well as when surgical treatment is required.

| S-EPMC7196403 | biostudies-literature

The early use of sepsis scores to predict respiratory failure and mortality in non-ICU patients with COVID-19? Utilidad de las escalas de sepsis para predecir el fallo respiratorio y la muerte en pacientes con COVID-19 fuera de las Unidades de Cuidados Intensivos

Project description:This observational retrospective study aimed to investigate the usefulness of Sequential Organ Failure Assessment (SOFA), Quick SOFA (qSOFA), National Early Warning Score (NEWS), and quick NEWS in predicting respiratory failure and death among patients with COVID-19 hospitalized outside of intensive care units (ICU). We included 237 adults hospitalized with COVID-19 who were followed-up on for one month or until death. Respiratory failure was defined as a PaO2/FiO2 ratio ? 200 mmHg or the need for mechanical ventilation. Respiratory failure occurred in 77 patients (32.5%), 29 patients (12%) were admitted to the ICU, and 49 patients (20.7%) died. Discrimination of respiratory failure was slightly higher in NEWS, followed by SOFA. Regarding mortality, SOFA was more accurate than the other scores. In conclusion, sepsis scores are useful for predicting respiratory failure and mortality in COVID-19 patients. A NEWS score ? 4 was found to be the best cutoff point for predicting respiratory failure.

| S-EPMC7888251 | biostudies-literature

Mortality associated with cardiovascular disease in patients with COVID-19? Mortalidad asociada a las enfermedades cardiovasculares en pacientes con COVID-19

Project description:Introduction and objectives Cardiovascular disease (CVD) has been outlined as a possible risk factor for poorer outcomes in patients with COVID-19. Methods A meta-analysis was performed with currently available studies that report the prevalence of CVD in survivors vs non-survivors in patients with COVID-19 using reports available at 16 July 2020. Analyses were performed by a random effects model and sensitivity analyses were performed for the identification of potential sources of heterogeneity or to assess the small-study effects. Results A total of 307 596 patients from 16 reports were included and 46 321 (15.1%) had CVD. Globally, mortality rate was 8.2% (20 534 patients) and mortality rates were higher in hospital registries (48.7%) compared to national reports (23.1%). A total of 11 213 (24.2%) patients with CVD died and mortality rates were also higher in hospital registries (48.7%) compared to national reports (23.1%). CVD was associated to a 4-fold higher risk of mortality (OR, 4.33; 95%CI, 3.16–5.94). Data from 28 048 patients with diabetes was available. Diabetes was associated to higher mortality risk (OR, 2.41; 95%CI, 1.79–3.26; P < .001). From 40 173 subjects with hypertension it was concluded that hypertension was also a risk factor for higher mortality (OR, 2.60; 95%CI, 2.10–3.21; P < .001). Conclusions Patients with CVD and COVID-19 have a 4-fold higher risk of death. Diabetes and hypertension are also associated with higher mortality risk.

| S-EPMC7587172 | biostudies-literature

Neumopatias hospitalarias en pacientes con ventilacion mecanica.

Project description:Las neumopatías son la primera causa de infección hospitalaria en reanimación. Las neumopatías hospitalarias en los pacientes con ventilación mecánica (NHPVM) ocurren después de al menos 48 horas de ventilación mecánica invasiva. Su mecanismo es multifactorial, pero la opinión predominante es que obedecen a una inhalación posterior a la colonización orofaríngea, gástrica o traqueal. El retraso en la manifestación permite clasificar las NHPVM en precoces o tardías según se desarrollen antes o después del 5.° día de ventilación mecánica. La clínica puede ayudar al diagnóstico, sobre todo mediante la CPIS (Clinical Pulmonary Infection Score) y también es útil el lavado broncoalveolar (LBA), que parece la mejor prueba para el diagnóstico microbiológico. El diagnóstico diferencial se plantea con una neumopatía no bacteriana o incluso no infecciosa (neoplásica, inflamatoria, fibrosante) en la que siempre debe plantearse la búsqueda de otro foco infeccioso en función de la orientación clínica inicial o del fracaso de la antibioticoterapia. El uso preferente de la ventilación no invasiva, cuando es posible, parece que ayuda a prevenir el desarrollo de la neumopatía hospitalaria. La posición inclinada 30-45° del paciente es la única medida preventiva verdaderamente validada en las NHPVM. El tratamiento curativo de las neumopatías bacterianas descansa por lo general en un tratamiento antibiótico doble, que puede orientarse por los datos de muestras obtenidas con métodos no invasivos como las aspiraciones traqueales efectuadas de forma periódica y sistemática. La duración del tratamiento es discutible, pero los últimos datos apoyan un tratamiento con antibióticos relativamente corto, de 8 días.

| S-EPMC7158992 | biostudies-literature

Role of 3D printing in the protection of surgical and critical care professionals in the COVID-19 pandemic☆ Papel de la impresion 3D para la proteccion de los profesionales del area quirurgica y criticos en la pandemia de COVID-19

Project description:Background and objective There is a shortage of supplies for the protection of professionals during the COVID-19 pandemic. 3D printing offers the possibility to compensate for the production of some of the equipment needed. The objective is to describe the role of 3D printing in a health service during the COVID-19 pandemic, with an emphasis on the process to develop a final product ready to be implemented in the clinical environment. Methods A working group was formed between the healthcare administration, clinicians and other public and private institutions in Cantabria, Spain coordinated by the Valdecilla Virtual Hospital. The process included receiving the printing proposals, learning about the printing resources in the region, selecting the devices, creating a team for each project, prototyping, evaluation and redesign, manufacturing, assembly and distribution. Results The following supplies are produced: 1) devices that help protect providers: face protection screens (2400 units), personalized accessories for photophores (20 units) and ear-protection forks for face-masks (1200 units); 2) products related to the ventilation of infected patients: connectors for non-invasive ventilation systems; and 3) oral and nasopharyngeal swabs (7500 units) for the identification of coronavirus carriers with the aim of designing action protocols in clinical areas. Conclusions 3D printing is a valid resource for the production of protective material for professionals whose supply is reduced during a pandemic.

| S-EPMC7546187 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data